Loading...
  • clinical
  • The intensity of T-cell response induced by the vaccine was correlated with clinical response. (aacrjournals.org)
  • In this issue of Clinical Cancer Research , van Poelgeest and colleagues report the clinical results of a therapeutic human papillomavirus (HPV) vaccine for the treatment of premalignant anogenital lesions ( 1 ). (aacrjournals.org)
  • The vaccine itself did not appear to be the critical element to explain the differential clinical activity of THV, as the clinical impact of HPV vaccines was only observed in patients with premalignant HPV-associated lesions, whereas none of the vaccines displayed any clinical activity in established cancer. (aacrjournals.org)
  • The potential of the current licensed preventive virus-like particle (VLP) human papillomavirus (HPV) vaccines to have a major public health impact is leading to additional clinical trials. (nih.gov)
  • Immunization protocols were tested in a preventive or therapeutic pre-clinical mouse model of HPV-16 tumorigenicity using heterologous (DNA/FP) or homologous (DNA/DNA and FP/FP) prime/boost regimens. (biomedcentral.com)
  • Despite these advantages and initial high hopes, research progress in this area since the first report about two decades ago has been slow, with only a few DNA vaccines reaching clinical trials to date , . (pubmedcentralcanada.ca)
  • In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15) women with advanced metastatic cancer of the cervix. (drugs.com)
  • Under the agreement Vaxart will produce an oral vaccine containing certain proprietary antigens from Janssen, and test the product in a pre-clinical challenge model. (yahoo.com)
  • Data available from a few clinical trials that enrolled subjects with CINs regardless of the HPV type(s) present demonstrated clinical responses, as measured by CIN regression, in subjects with both vaccine-matched and nonvaccine HPV types. (asm.org)
  • We believe our oral vaccine programs are significantly de-risked based on the positive clinical outcome of the BARDA-funded H1N1 influenza Phase 2 challenge study which serves as proof of concept for our technology platform as a whole," continued Latour, "and we look forward to taking our norovirus vaccine into a Phase 2 challenge study next. (pharmiweb.com)
  • In clinical studies to date, Vaxart vaccines consistently generated broad systemic and local immune responses that could provide important advantages in preventing infection, as well as robust T cell responses that we believe are essential to obtain a therapeutic benefit in chronic viral infection and cancer. (pharmiweb.com)
  • immunization
  • In the therapeutic protocol, in-vivo experiments resulted in a higher number of tumor-free mice after the homologous DNA/DNA or heterologous DNA/FP immunization. (biomedcentral.com)
  • Here we investigated CD8 + T cell responses in the female mouse cervicovaginal mucosa after intravaginal immunization with human papillomavirus vectors (HPV pseudoviruses) that transiently expressed a model antigen, respiratory syncytial virus (RSV) M/M2, in cervicovaginal keratinocytes. (jci.org)
  • Vaxart
  • Development of a universal flu vaccine is a high priority public health objective and we are delighted to be working with Janssen in this important field," said Wouter Latour, M.D., chief executive officer of Vaxart. (yahoo.com)
  • Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. (yahoo.com)
  • Our oral tablet vaccine elicited a substantial serum antibody response as well as a strong local intestinal immune response as measured by mucosal homing B-cells and a greater than tenfold increase in fecal IgA antibodies," said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart. (biospace.com)
  • We believe our tablet vaccine could provide an optimal solution to help reduce the burden of disease in vulnerable populations such as the elderly and the very young, as well as people at-risk in the healthcare, travel and food industry," said David Taylor, M.D., chief medical officer of Vaxart. (biospace.com)
  • We are thrilled with the prospect of combining forces with Aviragen, which will create a deep pipeline of antiviral products and allow Vaxart to accelerate development of the promising vaccine candidates that are based on our proprietary oral delivery platform," said Wouter Latour, M.D., Chief Executive Officer of Vaxart. (pharmiweb.com)
  • The Vaxart technology platform has been engineered for the delivery of a wide range of oral vaccines, initially targeting norovirus, human papilloma virus (HPV), respiratory syncytial virus, and influenza, using a convenient and room temperature-stable tablet, which eliminates the need for injection. (pharmiweb.com)
  • Vaxart is well-funded to advance its norovirus and HPV antiviral vaccine programs, and together with BTA074, the combined companies are poised to provide meaningful value-creating data readouts. (pharmiweb.com)
  • To date, Vaxart has dosed more than 300 adult volunteers with its vaccines for norovirus, respiratory syncytial virus and influenza. (pharmiweb.com)
  • HPV16
  • van Poelgeest and colleagues report the ability of ISA 101 vaccine [13 HPV16 E6 and E7 synthetic long peptides mixed with the Montanide adjuvant] without additional treatment to induce objective partial or complete histologic regression of the lesions in more than 50% of patients with high-grade vulvar (VuVIN3) and vaginal intraepithelial neoplasia (VaIN3) with a follow-up of 12 months ( 1 ). (aacrjournals.org)
  • These results extend recent findings from a randomized control trial based on an HPV DNA vaccine, which induced regression of HPV16- or HPV18-positive CIN2/3 in 48.2% of cases compared with a spontaneous regression rate of 30% in the placebo arm ( 3 ). (aacrjournals.org)
  • Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. (cancer.gov)
  • Epitope
  • NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Oct 8, 2009 - Advaxis, Inc . (OTCBB: ADXS) , the live, attenuated Listeria monocytogenes ( Lm ) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company's proprietary technology that targets tumor blood vessels (anti angiogenic antigen). (drugs.com)
  • Epitope spreading is a mechanism which can provide a continued therapeutic response when escape mutations arise in one or another antigen. (drugs.com)
  • The finding of epitope spreading adds to the growing list of therapeutic mechanisms associated with live Lm therapy. (drugs.com)
  • Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. (semanticscholar.org)
  • Mutation in a 17D-204 Vaccine Substrain-Specific Envelope Protein Epitope Alters the Pathogenesis of Yellow Fever Virus Mice", Virol. (lens.org)
  • immunizations
  • Three sequential immunizations with AcHERV-HP18L1 DNA vaccine followed by three repeated dosing with AcHERV-HP16L1 over 11 weeks induced an initial production of anti-HPV18L1 antibody followed by subsequent induction of anti-HPV16L1 antibody. (pubmedcentralcanada.ca)
  • oral tablet
  • Norovirus is the leading cause of acute viral gastroenteritis in the United States, causing frequent outbreaks across the population, and we believe our oral tablet vaccine would be the optimal approach to address this unmet medical need. (pharmiweb.com)
  • Development
  • One approach in the development of HPV therapeutic vaccines is the use of agonist epitopes that would elicit enhanced cytotoxic T-lymphocyte (CTL) responses capable of lysing human tumor cells expressing native HPV epitopes. (cancer.gov)
  • One major limitation that has hampered the successful development of DNA vaccines is the intracellular delivery issue. (pubmedcentralcanada.ca)
  • In this timely book leading scientists review current aspects of papillomavirus research providing a fascinating insight into papillomavirus molecular biology, interactions with the host, immunology and vaccine development. (caister.com)
  • Essential reading for scientists and researchers working on papillomavirus and a recommended text for anyone involved with antiviral drug and vaccine development. (caister.com)
  • For further information on influenza, its burden on human health and vaccine development, please visit the CDC website at www.cdc.gov/flu/ . (yahoo.com)
  • antiviral
  • Teslexivir is a topical antiviral agent that is a potent and selective inhibitor of the interaction between two essential viral proteins, E1 and E2, an interaction that is a necessary step for human papillomavirus (HPV) types 6 and 11 DNA replication and thus viral production. (pharmiweb.com)
  • antibodies
  • The intramuscular administration of AcHERV-based HPV16L1 and HPV18L1 DNA vaccines induced antigen-specific serum IgG, vaginal IgA, and neutralizing antibodies to levels comparable to those achieved using the commercially marketed vaccine Cervarix. (pubmedcentralcanada.ca)
  • We are advancing a therapeutic vaccine for smoking cessation that induces antibodies to nicotine. (selectabio.com)
  • In October, at ID Week in San Francisco, the Company presented data from its H1 influenza Phase 2 challenge study demonstrating that its oral H1 flu vaccine, while providing 39% reduction in flu illness compared to 27% for Fluzone ® , protected primarily through mucosal immunity, in contrast to Fluzone which primarily protected through serum antibodies. (theusdaily.com)
  • antibody
  • In addition, more than 80% of recipients of the high dose vaccine developed mucosally-primed norovirus specific circulating antibody secreting cells, IgA positive memory B cells expressing the α4β7 gut homing receptor, and fecal IgA. (biospace.com)
  • As reported in the article, the vaccine generated robust systemic and mucosal immune responses, including mucosal IgA, memory B cells, and serum blocking antibody titers (BT50), all potential correlates of protection. (theusdaily.com)
  • candidate
  • We are focused on our lead product candidate, the first oral vaccine against norovirus, a disease with a $34 billion economic impact in high income countries including the United States, Europe and Japan. (theusdaily.com)
  • As described in the article, the oral RSV-F vaccine candidate provided complete sterilizing protection against RSV infection in the cotton rat challenge model at the target dose. (theusdaily.com)
  • mucosal
  • and Vaxart's expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV. (yahoo.com)
  • tumor
  • This vaccine not only attacked its target antigen but induced immune activation against a different tumor antigen Her2/neu, even though the vaccine did not target Her2/neu. (drugs.com)
  • Further, this vaccine attacked both tumor blood vessel formation and directly attacked tumor cells that displayed Her2. (drugs.com)
  • Based on our observations, we believe our therapeutic vaccines can reduce tumor size and increase survival rate and may have synergistic effects with certain checkpoint inhibitors. (selectabio.com)
  • peptides
  • an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). (clinicaltrials.gov)